Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Imagion Biosystems Ltd. ( (AU:IBX) ) has provided an update.
Imagion Biosystems has successfully secured AU$3 million in capital to advance its MagSense® molecular MRI imaging technology and has resumed collaboration with Siemens for its molecular MRI program. The company is prioritizing the FDA IND filing for its MagSense® HER2 Breast Cancer imaging, with plans to start a Phase 2 study in the second half of 2025. The capital raise has improved the company’s cash position significantly, enabling further development of their technology and exploration of strategic partnerships to improve imaging quality and cancer detection sensitivity.
More about Imagion Biosystems Ltd.
Imagion Biosystems Ltd. is a healthcare company focused on improving cancer detection through advanced imaging technologies. Its primary product, the MagSense® molecular MRI imaging technology, aims to enhance early cancer detection, with a market focus on imaging agents for various cancers, including breast, prostate, and ovarian cancer.
YTD Price Performance: -5.00%
Average Trading Volume: 921,621
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$3.83M
For an in-depth examination of IBX stock, go to TipRanks’ Stock Analysis page.
